+ All Categories
Home > Documents > How to Analyze Therapy in the Medical Literature (part 2)

How to Analyze Therapy in the Medical Literature (part 2)

Date post: 13-Jan-2016
Category:
Upload: chaim
View: 34 times
Download: 3 times
Share this document with a friend
Description:
How to Analyze Therapy in the Medical Literature (part 2). Akbar S oltani. MD . Tehran University of Medical Sciences (TUMS) Shariati Hospita l www.soltaniebm.com. Objectives. Review different concepts such as - PowerPoint PPT Presentation
Popular Tags:
32
How to Analyze Therapy in the Medical Literature (part 2) Akbar Soltani. MD. Tehran University of Medical Sciences (TUMS) Shariati Hospital www.soltaniebm.com
Transcript
Page 1: How to Analyze Therapy in the Medical Literature (part 2)

How to Analyze Therapy in the Medical Literature

(part 2)

Akbar Soltani. MD.Tehran University of Medical Sciences (TUMS)

Shariati Hospitalwww.soltaniebm.com

Page 2: How to Analyze Therapy in the Medical Literature (part 2)

Objectives

• Review different concepts such as– Relative Risk , Absolute Risk Reduction, Relative Risk

Reduction, Number Needed to Treat

• Measures of precision of effects such as P value or confidence interval?

• Principles of application of the results to patient care?

Page 3: How to Analyze Therapy in the Medical Literature (part 2)

Three Step Guide in Using an Article to Assess Therapy

1. Are the results of the study valid?

2. What are the results? What measures of precision of effects were reported (CIs, p-values)?

3. How can I apply these results to patient care?

Page 4: How to Analyze Therapy in the Medical Literature (part 2)

Measuring Risk: Relative Risk

Treated Placebo

Patients with HT 2365 2371

Strokes 96 149

Rate 0.04 0.06

Relative Risk (RR) = rate in exposed = 0.04 = 0.67

rate in nonexposed 0.06

SHEP. JAMA. 1991;265:3255-3264

Page 5: How to Analyze Therapy in the Medical Literature (part 2)

Communicating risk:

10%

5%

10%

20% 20%

40%

RRR=?ARR=?

placebo

Page 6: How to Analyze Therapy in the Medical Literature (part 2)

Measuring Risk: Relative Risk

Treated Placebo

Patients with HT 2365 2371

Strokes 96 149

Rate 0.04 0.06

Relative Risk (RR) = rate in exposed = 0.04 = 0.67

rate in nonexposed 0.06

SHEP. JAMA. 1991;265:3255-3264

4% 6%

Page 7: How to Analyze Therapy in the Medical Literature (part 2)

Measuring Risk: ARR?

6%

4%

2%

Page 8: How to Analyze Therapy in the Medical Literature (part 2)

Measuring Risk:Absolute Risk Reduction

Absolute Risk Reduction (ARR) is the absolute difference in event rates between the experimental and control patients.

Calculated by:

ARR = CER - EER = 0.06 - 0.04 = 0.02

In its decimal form the ARR is not easy to use!

Converted to a percentage - there is an absolute risk reduction of 2%

Page 9: How to Analyze Therapy in the Medical Literature (part 2)

Measuring Risk: RRR?

6%

4%

2%

Page 10: How to Analyze Therapy in the Medical Literature (part 2)

Measuring Risk:Relative Risk Reduction

Relative Risk Reduction (RRR) is the proportional reduction in event rates between the experimental and control patients.

Two ways to calculate:RRR = (1 - RR) = (1 - 0.67) = 0.33

ORRRR = CER - EER = 0.06 - 0.04 = 0.33

CER 0.06

Therefore, treatment reduced the stroke rate by 33% OR a RRR of 33% means that the new treatment reduced the

risk of death by 33% relative to that occurring among control patients

CER = control event rate

EER = experimental event rate

Page 11: How to Analyze Therapy in the Medical Literature (part 2)

Usefulness of the ARR:Number Needed to Treat

Number Needed to Treat (NNT) is the number of patients a clinician needs to treat in order to prevent one additional adverse outcome.

NNT is for dichotomous outcomes.

Calculated by:NNT = 1/ARR = 1/0.02 = 50

Therefore, you would have to treat 50 hypertensive patients to prevent one stroke.

Page 12: How to Analyze Therapy in the Medical Literature (part 2)

Number Needed to Treat

CER=0.06=100----------6

EER=0.04=100----------4

SO: 100-----------2

X------------1

50-----------1Calculated by:

NNT = 1/ARR = 1/0.02 = 50

Therefore, you would have to treat 50 hypertensive patients to prevent one stroke.

Page 13: How to Analyze Therapy in the Medical Literature (part 2)

Why not just use RRR? PTH trial

CER = 6 % Age =70 + 7

EER = 3 %

ARR = CER – EER = 3%

NNT = 1/ARR = 1/ 0.03 = 33

CER = 1/1000 Age = 55 + 5

EER = 1/2000

ARR=1/1000-1/2000=1/2000

NNT = 1/ARR= 2000

Page 14: How to Analyze Therapy in the Medical Literature (part 2)

Why not just use RRR?

CER EER RRR ARR NNT

0.6 0.4 33% 20% 5

0.06 0.04 33% 2% 50

0.006 0.004 33% .2% 500

RRR remains the same despite differences in absolute rate of events.

Page 15: How to Analyze Therapy in the Medical Literature (part 2)

Why not just use RRR?

CER EER RRR ARR NNT

0.6 0.4 33% 20% 5

0.06 0.04 33% 2% 50

0.006 0.004 33% .2% 500

ARRs reflect underlying susceptibility of patients and provides more complete information.

Page 16: How to Analyze Therapy in the Medical Literature (part 2)

Why not just use RRR?

CER EER RRR ARR NNT

0.6 0.4 33% 20% 5

0.06 0.04 33% 2% 50

0.006 0.004 33% .2% 500

NNTs provide a useful measure of the clinical effort that must be expended to avoid bad events.

Page 17: How to Analyze Therapy in the Medical Literature (part 2)

Randomised trial of cholesterol lowering in 4,444 patients with CHD: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994: 344; 1383-1389

• 4,444 patients recruited as a sample• inclusion criteria

– CHD and cholesterol 5.5 - 8 mmol/l• exclusion criteria

– planned cardiac surgery, HF, child bearing potential

• simvastatin Vs. placebo• double blind• Outcomes

– mortality, major coronary events, admissions for acute CHD, incidence of revascularisation procedures

Page 18: How to Analyze Therapy in the Medical Literature (part 2)

4S Study: self evaluation

• Median follow up 5.4 y

• analyse by intention to treat

• Significant reduction in all cause mortality– 11.5% placebo Vs. 8.2% simvastatin– ARR = – RRR = – NNT = patients with CHD and cholesterol

5.5 - 8 need to treated with simvastatin (20 mg) for 5.4 years to save one life

Page 19: How to Analyze Therapy in the Medical Literature (part 2)

4S Study Cont’d

• Median follow up 5.4 y

• analyse by intention to treat

• Significant reduction in all cause mortality– 11.5% placebo Vs. 8.2% simvastatin– ARR = 11.5 - 8.2 = 3.3%– RRR = (11.5 - 8.2)/11.5 = 29%– NNT = 1/ARR = 30

• 30 patients with CHD and cholesterol 5.5 - 8 need to treated with simvastatin (20 mg) for 5.4 years to save one life

Page 20: How to Analyze Therapy in the Medical Literature (part 2)

Why NNT is not enough

• NNT for continuous outcome is difficult to calculate

• Time can be added to calculations cautiously • We can not compare NNTs from different

studies easily• Example: 2 RCT (Risedronate) 2 NNT! Can

we say Risedronate is better than Risedronate!

Page 21: How to Analyze Therapy in the Medical Literature (part 2)

Three Step Guide in Using an Article to Assess Therapy

1. Are the results of the study valid?

2. What are the results? What measures of precision of effects were reported (CIs, p-values)?

3. How can I apply these results to patient care?

Page 22: How to Analyze Therapy in the Medical Literature (part 2)

P Value or CI?

Page 23: How to Analyze Therapy in the Medical Literature (part 2)

P Value or CI?

Page 24: How to Analyze Therapy in the Medical Literature (part 2)

P Value or CI?

Page 25: How to Analyze Therapy in the Medical Literature (part 2)

P Value or CI?

Page 26: How to Analyze Therapy in the Medical Literature (part 2)

P Value or CI?

Page 27: How to Analyze Therapy in the Medical Literature (part 2)

P Value or CI?

Page 28: How to Analyze Therapy in the Medical Literature (part 2)

Confidence Intervals for Small Numerators

• Example: A new drug is given to 60 people. It seems to work, and has no serious adverse effects.

• The authors conclude it is "safe and effective." The upper limit for the 95% CI for any serious adverse effect is, or 5%.

• 95% confident of adverse event = 0/n – 3/n

Page 29: How to Analyze Therapy in the Medical Literature (part 2)

Another example from textbooks!

• Based on one observational study in 94 women, no one report adverse reactions.

• Rule of 3: 3/94=upper limit of adverse effects that may not have been seen.

Page 30: How to Analyze Therapy in the Medical Literature (part 2)

Three Step Guide in Using an Article to Assess Therapy

1. Are the results of the study valid?

2. What are the results? What measures of precision of effects were reported (CIs, p-values)?

3. How can I apply these results to patient care?

Page 31: How to Analyze Therapy in the Medical Literature (part 2)

How can I apply the results to patient care?

• Were the study patients similar to my patient?

• Were all clinically important outcomes considered?

• Are the likely treatment benefits worth the potential harm and costs?

Page 32: How to Analyze Therapy in the Medical Literature (part 2)

Thank you


Recommended